: FDA advisers vote in favor of AstraZeneca, Sanofi antibody for infant RSV protection


Advisers to the U.S. Food and Drug Administration voted unanimously Thursday to recommend a monoclonal antibody developed by Sanofi SNY, +1.30% and AstraZeneca AZN, +1.28% to protect infants from respiratory syncytial virus. RSV is a common respiratory virus that can cause severe illness in infants and older adults. In a separate vote, 19 of 21 members voted to recommend the monoclonal antibody, nirsevimab, for prevention of RSV lower respiratory disease in children up to two years of age who remain vulnerable to severe RSV. FDA advisory-committee votes are not binding, but the agency often follows committee recommendations. Shares of Sanofi and AstraZeneca were both up 1.3% on Thursday. 

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleEarnings Results: DocuSign stock rally cools as execs talk about tough macro after earnings, outlook beat
Next articleThe Moneyist: ‘I worry about outliving my money’: I’m a 65-year-old widow in good health. Should I wait until 70 to collect my pension?


Please enter your comment!
Please enter your name here